Radiotherapy for salivary gland cancer : REFCOR recommendations by the formal consensus method
Copyright © 2023 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes.
MATERIAL AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method.
RESULTS: Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered.
CONCLUSION: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
European annals of otorhinolaryngology, head and neck diseases - (2023) vom: 28. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thariat, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hadrontherapy |
|---|
| Anmerkungen: |
Date Revised 29.11.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.anorl.2023.11.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365215864 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365215864 | ||
| 003 | DE-627 | ||
| 005 | 20231226101209.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anorl.2023.11.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1217.xml |
| 035 | |a (DE-627)NLM365215864 | ||
| 035 | |a (NLM)38030445 | ||
| 035 | |a (PII)S1879-7296(23)00158-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thariat, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiotherapy for salivary gland cancer |b REFCOR recommendations by the formal consensus method |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes | ||
| 520 | |a MATERIAL AND METHODS: The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method | ||
| 520 | |a RESULTS: Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered | ||
| 520 | |a CONCLUSION: Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors | ||
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Hadrontherapy | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Salivary gland cancer | |
| 700 | 1 | |a Ferrand, F-R |e verfasserin |4 aut | |
| 700 | 1 | |a Fakhry, N |e verfasserin |4 aut | |
| 700 | 1 | |a Even, C |e verfasserin |4 aut | |
| 700 | 1 | |a Vergez, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chabrillac, E |e verfasserin |4 aut | |
| 700 | 1 | |a Sarradin, V |e verfasserin |4 aut | |
| 700 | 1 | |a Digue, L |e verfasserin |4 aut | |
| 700 | 1 | |a Troussier, I |e verfasserin |4 aut | |
| 700 | 1 | |a Bensadoun, R-J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of otorhinolaryngology, head and neck diseases |d 2010 |g (2023) vom: 28. Nov. |w (DE-627)NLM201398648 |x 1879-730X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:28 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anorl.2023.11.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 28 |c 11 | ||